Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Notice of Results
Oxford, UK - 21 February 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, expects to announce its results for the year ended 30 September 2024 on Friday 28 February 2025.
-Ends-
For further details please contact:
| Oxford BioDynamics Plc Iain Ross, Executive Chairman Paul Stockdale, CFO
| +44 (0)1865 518910
|
| Shore Capital - Nominated Adviser and Joint Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy
| +44 (0)20 7408 4090
|
| OAK Securities - Joint Broker Jerry Keen / Henry Clarke / Damion Carruel
| +44 (0)203 973 3678 |
| WG Partners - Joint Broker David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
| +44 (0)20 3705 9330 |
| Vigo Consulting - Media / Analyst enquiries for OBD | +44 (0)20 7390 0230 obd@vigoconsulting.com
|
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.